A panelist discusses how the CONTACT-03 and TiNivo-2 studies yielded important insights about ICI rechallenge and tivozanib in the post-ICI setting, with particular attention to the notable 9.2-month median PFS with tivozanib monotherapy, the impact of dosing strategies, and the timing of therapy initiation, though questions remain about the broader implications for ICI rechallenge efficacy across different treatment contexts.
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.
Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings.
Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.
Panelists discuss second-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on available therapies and personalized approaches based on patient characteristics.
Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual Meeting.
David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.
Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response patterns, and strategic consideration of future therapeutic options to maintain long-term disease control.
Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against potential risks and benefits, with consideration of disease trajectory and patient-specific factors to optimize long-term outcomes.
Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 study.
Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials including Study 205, METEOR, CONTACT-03, TIVO-3, TiNivo-2, and LITESPARK-005, which have demonstrated varying efficacy across different patient populations and prior therapies, particularly noting the impact of prior immunotherapy exposure on treatment selection and the need for careful consideration of historical trial data in the context of modern treatment paradigms.
An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.
A panelist discusses how second-line therapy goals typically shift from pursuing complete remission (as in first-line treatment) to focusing more on disease control, quality of life management, and balancing treatment effectiveness with tolerability based on the patient's prior therapy experience.
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community oncologists.
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.
Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.
Olalekan O Oluwole, MD, MBBS, discusses the background and rationale of the research he contributed to, which was presented at the 2025 Transplantation & Cellular Therapy Meetings.
Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.
Panelists discuss how complex cases of advanced myelofibrosis can be managed using evidence-based treatment algorithms, considering factors such as disease progression, prior therapies, and challenging complications.
Panelists discuss how clinicians can effectively manage patients with high-risk myelofibrosis with cytopenias through careful treatment selection, dose modification strategies, and monitoring of hematologic parameters.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss some specific practices and policies that have been most effective at their institution and how these may be adopted by other practices.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss how medical mistrust has impacted participation in oncology clinical trials.